Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis — Subgroup Analyses of the CALIPSO Trial

INTRODUCTION: Coronary artery calcium (CAC) is highly prevalent and linked with poor outcomes in patients receiving maintenance hemodialysis, and its reduction may improve patient prognosis. SNF472, a selective inhibitor of hydroxyapatite crystallization, slows CAC progression in patients receiving...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Kidney Int Rep
Egile Nagusiak: Raggi, Paolo, Bellasi, Antonio, Sinha, Smeeta, Bover, Jordi, Rodriguez, Mariano, Ketteler, Markus, Bushinsky, David A., Garg, Rekha, Perelló, Joan, Gold, Alex, Chertow, Glenn M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2020
Gaiak:
Clinical Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7710828/
https://ncbi.nlm.nih.gov/pubmed/33305110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ekir.2020.09.032
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak